Roche/Ipsen's Suspended Taspoglutide Could Be Another Diabetes Casualty
This article was originally published in Pharmaceutical Approvals Monthly
Roche's decision to halt dosing in a trial of the GLP-1 receptor agonist taspoglutide following an announcement of a major development delay illustrates the intensively competitive nature of the diabetes market
You may also be interested in...
Swiss pharma cites U.S. and EU health care spending constraints and regulatory setbacks as reasons for plan.
DPP-4 drug dutogliptin was a casualty of the highly competitive, regulated and expensive space for diabetes drug development.
Roche has voluntarily initiated a risk mitigation strategy to identify patients likely to develop troublesome hypersensitivity reactions and estimates a 12-18 month delay in the development program for the type 2 diabetes therapy.